\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ sided\\ proptosis\\,\\ otherwise\\ wnl\ \(0\)\
\-\ this\\ patient\\ has\\ been\\ treated\\ with\\ chemotherapy\\ since\\ august\\ 2004\\ due\\ to\\ the\\ proptosis\\ caused\\ by\\ the\\ mass\\.\\ chemotherapy\\ agents\\ include\\ carboplatin\\ and\\ vincristine\\.\\ thus\\ far\\ the\\ mass\\ has\\ had\\ a\\ minimal\\ decrease\\ in\\ size\\.\ \(0\)\
\-\ right\\ sided\\ intraconal\\ solid\\ spherical\\ mass\\ continuous\\ with\\ the\\ optic\\ nerve\\.\\ meninges\\ appear\\ to\\ be\\ intact\\ around\\ mass\\ with\\ csf\\ surrounding\\ mass\\.\\ mass\\ appears\\ to\\ be\\ confined\\ within\\ orbit\\ and\\ does\\ not\\ involve\\ the\\ optic\\ chiasm\\.\\ the\\ signal\\ intensity\\ of\\ the\\ mass\\ in\\ t1w\\ images\\ is\\ similar\\ to\\ the\\ signal\\ intensity\\ of\\ the\\ optic\\ nerves\\ and\\ brain\\ matter\\.\\ on\\ t2w\\ images\\,\\ the\\ mass\\ again\\ has\\ similar\\ intensity\\ to\\ the\\ optic\\ nerves\\ and\\ brain\\ matter\\ and\\ has\\ a\\ higher\\ intensity\\ than\\ the\\ musculature\\.\\ on\\ t1w\\ images\\,\\ post\\-gadolinium\\,\\ the\\ mass\\ shows\\ fairly\\ uniform\\ contrast\\ enhancement\ \(0\)\
\-\ optic\\ nerve\\ glioma\ \(11\)\
\-\ most\\ common\\ orbital\\ malignancies\\ of\\ children\\:\ \(0\)\
\-\ rhabdomyosarcoma\\ \\(primary\\)\ \(0\)\
\-\ neuroblastoma\\ \\(usually\\ metastatic\\)\ \(0\)\
\-\ retinoblastoma\\ \\(intraocular\\)\ \(0\)\
\-\ most\\ common\\ orbital\\ masses\\:\ \(0\)\
\-\ benign\\ cysts\\ \\(teratoma\\,\\ dermoid\\,\\ epidermoid\\,\\ congenital\\ cystic\\ eye\\)\ \(0\)\
\-\ vascular\\ lesions\\ \\(capillary\\ hemangioma\\,\\ cavernous\\ hemangioma\\,\\ avm\\,\\ lymphangioma\\)\ \(0\)\
\-\ neurogenic\\ orbital\\ masses\\ of\\ children\\:\ \(0\)\
\-\ optic\\ nerve\\ glioma\ \(11\)\
\-\ optic\\ sheath\\ meningioma\ \(1\)\
\-\ sphenoid\\ wing\\ meningioma\ \(0\)\
\-\ schwannoma\ \(67\)\
\-\ neurofibroma\ \(78\)\
\-\ less\\ common\\ considerations\\:\ \(0\)\
\-\ langerhans\\â\\€\\™\\ cell\\ histiocytosis\ \(0\)\
\-\ lacrimal\\ gland\\ lesions\\ \\(cysts\\,\\ tumors\\)\ \(0\)\
\-\ inflammatory\\ process\\ or\\ infection\ \(0\)\
\-\ 2\\ y\\.o\\.\\ noted\\ to\\ have\\ right\\ sided\\ proptosis\ \(1\)\
\-\ the\\ pediatric\\ patient\\ presenting\\ with\\ proptosis\\ should\\ always\\ make\\ the\\ clinician\\ think\\ of\\ rhabdomyosarcoma\\.\\ although\\ this\\ tumor\\ accounts\\ for\\ only\\ about\\ 10\\%\\ of\\ all\\ orbital\\ tumors\\,\\ it\\ is\\ the\\ most\\ common\\ primary\\ malignancy\\ of\\ the\\ orbit\\ and\\ is\\ rapidly\\ progressive\\ and\\ destructive\\.\\ for\\ this\\ reason\\,\\ children\\ with\\ proptosis\\,\\ decreased\\ vision\\,\\ or\\ ptosis\\ should\\ promptly\\ be\\ imaged\\ with\\ either\\ ct\\ or\\ mri\\ \\(ct\\ is\\ better\\ to\\ evaluate\\ for\\ bony\\ invasion\\ of\\ rhabdomyosarcoma\\)\\ to\\ evaluate\\ for\\ a\\ mass\\ suspicious\\ for\\ rhabdomyosarcoma\\.\\ other\\ masses\\ in\\ the\\ differential\\ include\\ orbital\\ cysts\\ \\(which\\ are\\ the\\ most\\ common\\ orbital\\ mass\\ and\\ generally\\ benign\\)\\,\\ vascular\\ lesions\\,\\ neurogenic\\ tumors\\ as\\ listed\\ above\\,\\ and\\ metastatic\\ disease\\ \\(of\\ which\\,\\ neuroblastoma\\ is\\ the\\ most\\ common\\ malignancy\\ to\\ metastasize\\ to\\ the\\ orbit\\)\\.\\ cysts\\ of\\ the\\ orbit\\ are\\ by\\ far\\ the\\ most\\ common\\,\\ with\\ dermoid\\ and\\ epidermoid\\ cysts\\ accounting\\ for\\ about\\ 30\\-46\\%\\ of\\ all\\ orbital\\ masses\\;\\ vascular\\ lesions\\ account\\ for\\ about\\ 15\\%\\;\\ neurogenic\\ tumors\\ and\\ metastatic\\ tumors\\ both\\ account\\ for\\ about\\ 2\\-3\\%\\ each\\.\ \(0\)\
\-\ this\\ patient\\ had\\ an\\ mri\\ series\\ of\\ the\\ orbits\\ done\\,\\ revealing\\ a\\ retrobulbar\\ mass\\ and\\ the\\ findings\\ listed\\ above\\.\\ with\\ the\\ mass\\ continuous\\ with\\ the\\ optic\\ nerve\\ and\\ encapsulated\\ by\\ the\\ optic\\ nerve\\ sheath\\,\\ it\\ makes\\ the\\ diagnosis\\ of\\ an\\ optic\\ nerve\\ tumor\\ much\\ more\\ likely\\ than\\ the\\ other\\ possible\\ diagnoses\\ in\\ the\\ differential\\.\\ as\\ the\\ mass\\ has\\ meninges\\ smoothly\\ lining\\ it\\ and\\ there\\ is\\ csf\\ visualized\\ between\\ the\\ mass\\ and\\ the\\ dura\\,\\ the\\ mass\\ is\\ most\\ likely\\ a\\ part\\ of\\ the\\ optic\\ nerve\\â\\€\\”leading\\ to\\ the\\ diagnosis\\ of\\ optic\\ nerve\\ glioma\\.\ \(0\)\
\-\ an\\ optic\\ nerve\\ glioma\\ is\\ actually\\ a\\ juvenile\\ pilocytic\\ astrocytoma\\ of\\ the\\ optic\\ nerve\\,\\ which\\ is\\ a\\ benign\\ and\\ usually\\ slow\\ growing\\ tumor\\.\\ ong\\ accounts\\ for\\ about\\ 20\\%\\ of\\ neurogenic\\ tumors\\ in\\ the\\ orbit\\,\\ there\\ is\\ possibly\\ a\\ mild\\ predilection\\ for\\ females\\,\\ and\\ it\\ usually\\ presents\\ by\\ 8\\ years\\ of\\ age\\.\\ the\\ presenting\\ signs\\ and\\ symptoms\\ are\\ typically\\ slow\\ progressing\\ painless\\ proptosis\\,\\ visual\\ loss\\,\\ nystagmus\\,\\ strabismus\\,\\ and\\ optic\\ atrophy\\ or\\ edema\\.\\ about\\ 29\\%\\ of\\ cases\\ are\\ associated\\ with\\ neurofibromatosis\\ type\\ i\\â\\€\\”typically\\ presenting\\ with\\ bilateral\\ optic\\ nerve\\ gliomas\\.\\ at\\ the\\ time\\ of\\ diagnosis\\,\\ about\\ 25\\-30\\%\\ of\\ gliomas\\ involve\\ only\\ the\\ intraorbital\\ optic\\ nerve\\,\\ about\\ 60\\-70\\%\\ of\\ gliomas\\ involve\\ the\\ chiasm\\,\\ of\\ which\\ about\\ 40\\%\\ have\\ invaded\\ surrounding\\ structures\\.\\ \ \(0\)\
\-\ management\\ of\\ optic\\ nerve\\ gliomas\\ is\\ typically\\ conservative\\,\\ involving\\ regular\\ interval\\ physical\\ exams\\ and\\ mri\\ imaging\\ to\\ evaluate\\ for\\ changes\\ in\\ size\\ \\(physical\\ exam\\ every\\ 6\\ months\\ and\\ mri\\ every\\ 1\\ year\\)\\.\\ this\\ is\\ because\\ ongs\\ are\\ benign\\,\\ slow\\ growing\\ tumors\\,\\ and\\ in\\ up\\ to\\ 80\\%\\ of\\ cases\\,\\ vision\\ does\\ decline\\ some\\ but\\ then\\ remains\\ stable\\.\\ surgical\\ and\\ radiologic\\ intervention\\ result\\ in\\ loss\\ of\\ vision\\ and\\ are\\ usually\\ only\\ offered\\ if\\ vision\\ loss\\ or\\ proptosis\\ progresses\\,\\ or\\ the\\ tumor\\ begins\\ invading\\ the\\ chiasm\\ or\\ hypothalamus\\.\\ chemotherapy\\ is\\ also\\ available\\ and\\ is\\ becoming\\ a\\ more\\ popular\\ form\\ of\\ treatment\\,\\ as\\ it\\ can\\ avoid\\ the\\ possible\\ complete\\ loss\\ of\\ vision\\ and\\ neurotoxic\\ effects\\ of\\ surgery\\ and\\ radiation\\.\\ chemotherapy\\ drugs\\ being\\ used\\ include\\ carboplatin\\ and\\ vincristine\\,\\ and\\ several\\ studies\\ have\\ recommended\\ that\\ chemotherapy\\ with\\ these\\ drugs\\ be\\ first\\-line\\ treatment\\ for\\ optic\\ nerve\\ gliomas\\ that\\ involve\\ the\\ chiasm\\ and\\/or\\ hypothalamus\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.43651959784474675\ \(0\)\
\-\ nerve\\:\\ 0\\.266562581350983\ \(0\)\
\-\ the\\:\\ 0\\.25029998731967473\ \(0\)\
\-\ proptosis\\:\\ 0\\.18849256978837284\ \(0\)\
\-\ about\\:\\ 0\\.17982668297369303\ \(0\)\
\-\ and\\:\\ 0\\.16545204173649636\ \(0\)\
\-\ orbital\\:\\ 0\\.16387186649827898\ \(0\)\
\-\ mass\\:\\ 0\\.16311510943528265\ \(0\)\
\-\ gliomas\\:\\ 0\\.15432514976969572\ \(0\)\
\-\ of\\:\\ 0\\.15146775827308737\ \(0\)\
\-\ tumors\\:\\ 0\\.13740151332120495\ \(0\)\
\-\ orbit\\:\\ 0\\.12359193389826859\ \(0\)\
\-\ neurogenic\\:\\ 0\\.11612298223946002\ \(0\)\
\-\ vision\\:\\ 0\\.1155772095524027\ \(0\)\
\-\ chiasm\\:\\ 0\\.11331042401313032\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.10803552944497986\ \(0\)\
\-\ common\\:\\ 0\\.10595221000061189\ \(0\)\
\-\ is\\:\\ 0\\.10232759153635428\ \(0\)\
\-\ cysts\\:\\ 0\\.1011229130805718\ \(0\)\
\-\ most\\:\\ 0\\.09723033794883457\ \(0\)\
\-\ for\\:\\ 0\\.09707276109851128\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.094756719206911\ \(0\)\
\-\ involve\\:\\ 0\\.09394787964351624\ \(0\)\
\-\ glioma\\:\\ 0\\.09069101277344362\ \(0\)\
\-\ to\\:\\ 0\\.0867403450955689\ \(0\)\
\-\ slow\\:\\ 0\\.07717454620789273\ \(0\)\
\-\ carboplatin\\:\\ 0\\.07679051865992798\ \(0\)\
\-\ intensity\\:\\ 0\\.07580537536552881\ \(0\)\
\-\ or\\:\\ 0\\.07427854430370417\ \(0\)\
\-\ benign\\:\\ 0\\.0733356686915352\ \(0\)\
\-\ masses\\:\\ 0\\.0726789283842644\ \(0\)\
\-\ it\\:\\ 0\\.06831002949004904\ \(0\)\
\-\ usually\\:\\ 0\\.06720823394217734\ \(0\)\
\-\ children\\:\\ 0\\.06560610342981021\ \(0\)\
\-\ loss\\:\\ 0\\.06504099992877709\ \(0\)\
\-\ meninges\\:\\ 0\\.064804066001739\ \(0\)\
\-\ hypothalamus\\:\\ 0\\.064804066001739\ \(0\)\
\-\ vincristine\\:\\ 0\\.06292627207852881\ \(0\)\
\-\ presenting\\:\\ 0\\.06272241297277374\ \(0\)\
\-\ with\\:\\ 0\\.06271376285071562\ \(0\)\
\-\ evaluate\\:\\ 0\\.06226216243720091\ \(0\)\
\-\ lesions\\:\\ 0\\.0613124376152931\ \(0\)\
\-\ listed\\:\\ 0\\.06100989010412829\ \(0\)\
\-\ has\\:\\ 0\\.06095503622528198\ \(0\)\
\-\ are\\:\\ 0\\.06076481473929641\ \(0\)\
\-\ accounts\\:\\ 0\\.05942004472028231\ \(0\)\
\-\ typically\\:\\ 0\\.056209061233075494\ \(0\)\
\-\ continuous\\:\\ 0\\.05602412420891885\ \(0\)\
\-\ tumor\\:\\ 0\\.05584072566413041\ \(0\)\
\-\ mri\\:\\ 0\\.054800180351339836\ \(0\)\
\-\ t1w\\:\\ 0\\.05469861686691284\ \(0\)\
\-\ far\\:\\ 0\\.0543519998648182\ \(0\)\
\-\ account\\:\\ 0\\.0543519998648182\ \(0\)\
\-\ drugs\\:\\ 0\\.05338310873065238\ \(0\)\
\-\ in\\:\\ 0\\.05311594418255627\ \(0\)\
\-\ sheath\\:\\ 0\\.05308122483628812\ \(0\)\
\-\ vascular\\:\\ 0\\.052860085877843445\ \(0\)\
\-\ growing\\:\\ 0\\.05236655787842041\ \(0\)\
\-\ every\\:\\ 0\\.05170262068348953\ \(0\)\
\-\ sided\\:\\ 0\\.05150423012815894\ \(0\)\
\-\ only\\:\\ 0\\.05002234417256235\ \(0\)\
\-\ nerves\\:\\ 0\\.04984816240617114\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.04904271158077237\ \(0\)\
\-\ which\\:\\ 0\\.04854400965496473\ \(0\)\
\-\ include\\:\\ 0\\.04764011179975931\ \(0\)\
\-\ epidermoid\\:\\ 0\\.04637484957061538\ \(0\)\
\-\ this\\:\\ 0\\.04585504435471888\ \(0\)\
\-\ by\\:\\ 0\\.04533571774017325\ \(0\)\
\-\ dermoid\\:\\ 0\\.04508911804305187\ \(0\)\
\-\ hemangioma\\:\\ 0\\.04490133403271762\ \(0\)\
\-\ metastatic\\:\\ 0\\.043913643655679915\ \(0\)\
\-\ be\\:\\ 0\\.04330752835609523\ \(0\)\
\-\ ong\\:\\ 0\\.042682395436819294\ \(0\)\
\-\ ongs\\:\\ 0\\.042682395436819294\ \(0\)\
\-\ neurotoxic\\:\\ 0\\.042682395436819294\ \(0\)\
\-\ csf\\:\\ 0\\.04217838918479929\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04150701545443708\ \(0\)\
\-\ similar\\:\\ 0\\.04068311714656057\ \(0\)\
\-\ matter\\:\\ 0\\.04064371671296952\ \(0\)\
\-\ have\\:\\ 0\\.03999867755727752\ \(0\)\
\-\ meningioma\\:\\ 0\\.03999810976709907\ \(0\)\
\-\ malignancy\\:\\ 0\\.039961485105265114\ \(0\)\
\-\ strabismus\\:\\ 0\\.03943930216764976\ \(0\)\
\-\ above\\:\\ 0\\.03850856846151595\ \(0\)\
\-\ popular\\:\\ 0\\.0375422142188444\ \(0\)\
\-\ images\\:\\ 0\\.03703707668429823\ \(0\)\
\-\ does\\:\\ 0\\.03690211167920724\ \(0\)\
\-\ invaded\\:\\ 0\\.03619620889848023\ \(0\)\
\-\ possible\\:\\ 0\\.03616730920765439\ \(0\)\
\-\ size\\:\\ 0\\.03614297216102824\ \(0\)\
\-\ cases\\:\\ 0\\.035903020830460666\ \(0\)\
\-\ retrobulbar\\:\\ 0\\.03564512627003904\ \(0\)\
\-\ intraorbital\\:\\ 0\\.03564512627003904\ \(0\)\
\-\ surrounding\\:\\ 0\\.03560000890413156\ \(0\)\
\-\ should\\:\\ 0\\.034829855027886096\ \(0\)\
\-\ intraocular\\:\\ 0\\.03470622930843394\ \(0\)\
\-\ differential\\:\\ 0\\.034683148497639635\ \(0\)\
\-\ intraconal\\:\\ 0\\.03392461756311784\ \(0\)\
\-\ think\\:\\ 0\\.03392461756311784\ \(0\)\
\-\ promptly\\:\\ 0\\.033577881584924314\ \(0\)\
\-\ brain\\:\\ 0\\.03327638580063172\ \(0\)\
\-\ primary\\:\\ 0\\.0328223838587528\ \(0\)\
\-\ metastasize\\:\\ 0\\.03266946547754927\ \(0\)\
\-\ spherical\\:\\ 0\\.0324020330008695\ \(0\)\
\-\ becoming\\:\\ 0\\.0324020330008695\ \(0\)\
\-\ as\\:\\ 0\\.032166414343549124\ \(0\)\
\-\ ptosis\\:\\ 0\\.03214906357921986\ \(0\)\
\-\ encapsulated\\:\\ 0\\.03214906357921986\ \(0\)\
\-\ retinoblastoma\\:\\ 0\\.031909072791624915\ \(0\)\
\-\ likely\\:\\ 0\\.031898026748849506\ \(0\)\
\-\ all\\:\\ 0\\.03177530250911793\ \(0\)\
\-\ lacrimal\\:\\ 0\\.031680793636118955\ \(0\)\
\-\ accounting\\:\\ 0\\.031680793636118955\ \(0\)\
\-\ offered\\:\\ 0\\.031680793636118955\ \(0\)\
\-\ progresses\\:\\ 0\\.03125515537362896\ \(0\)\
\-\ smoothly\\:\\ 0\\.03105602768050533\ \(0\)\
\-\ decline\\:\\ 0\\.03105602768050533\ \(0\)\
\-\ invading\\:\\ 0\\.03105602768050533\ \(0\)\
\-\ lining\\:\\ 0\\.03086502995393914\ \(0\)\
\-\ predilection\\:\\ 0\\.03086502995393914\ \(0\)\
\-\ progressing\\:\\ 0\\.03086502995393914\ \(0\)\
\-\ an\\:\\ 0\\.030617979156644996\ \(0\)\
\-\ revealing\\:\\ 0\\.03033478831575478\ \(0\)\
\-\ signal\\:\\ 0\\.03025909036656272\ \(0\)\
\-\ than\\:\\ 0\\.03025909036656272\ \(0\)\
\-\ lymphangioma\\:\\ 0\\.030170603238937083\ \(0\)\
\-\ clinician\\:\\ 0\\.030170603238937083\ \(0\)\
\-\ orbits\\:\\ 0\\.030170603238937083\ \(0\)\
\-\ malignancies\\:\\ 0\\.030011984842819556\ \(0\)\
\-\ reason\\:\\ 0\\.029710022360141156\ \(0\)\
\-\ nystagmus\\:\\ 0\\.029710022360141156\ \(0\)\
\-\ more\\:\\ 0\\.02931083151933879\ \(0\)\
\-\ begins\\:\\ 0\\.029290745478069008\ \(0\)\
\-\ august\\:\\ 0\\.029158939731699973\ \(0\)\
\-\ actually\\:\\ 0\\.029158939731699973\ \(0\)\
\-\ musculature\\:\\ 0\\.029030745559865005\ \(0\)\
\-\ wing\\:\\ 0\\.029030745559865005\ \(0\)\
\-\ dura\\:\\ 0\\.029030745559865005\ \(0\)\
\-\ physical\\:\\ 0\\.02894336976304555\ \(0\)\
\-\ imaged\\:\\ 0\\.028665979522455382\ \(0\)\
\-\ confined\\:\\ 0\\.02855044786058618\ \(0\)\
\-\ destructive\\:\\ 0\\.028437700366949422\ \(0\)\
\-\ diagnoses\\:\\ 0\\.028220042770094874\ \(0\)\
\-\ fairly\\:\\ 0\\.028012062104459425\ \(0\)\
\-\ capillary\\:\\ 0\\.028012062104459425\ \(0\)\
\-\ langerhans\\:\\ 0\\.028012062104459425\ \(0\)\
\-\ agents\\:\\ 0\\.02791143898810895\ \(0\)\
\-\ uniform\\:\\ 0\\.02791143898810895\ \(0\)\
\-\ other\\:\\ 0\\.027720620154338106\ \(0\)\
\-\ avoid\\:\\ 0\\.027716461002198874\ \(0\)\
\-\ effects\\:\\ 0\\.027716461002198874\ \(0\)\
\-\ considerations\\:\\ 0\\.027621936684769605\ \(0\)\
\-\ exams\\:\\ 0\\.02709169504658525\ \(0\)\
\-\ t2w\\:\\ 0\\.02692750996976755\ \(0\)\
\-\ sphenoid\\:\\ 0\\.026847528627676497\ \(0\)\
\-\ females\\:\\ 0\\.026847528627676497\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.02676889157365002\ \(0\)\
\-\ makes\\:\\ 0\\.02676889157365002\ \(0\)\
\-\ rapidly\\:\\ 0\\.02669155436532619\ \(0\)\
\-\ had\\:\\ 0\\.026595426893543217\ \(0\)\
\-\ right\\:\\ 0\\.02654606705802298\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.026466929090971623\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.026394388187093\ \(0\)\
\-\ juvenile\\:\\ 0\\.02625259568223316\ \(0\)\
\-\ patient\\:\\ 0\\.026042309046525484\ \(0\)\
\-\ make\\:\\ 0\\.02591584646253044\ \(0\)\
\-\ pilocytic\\:\\ 0\\.025601715456538967\ \(0\)\
\-\ treatment\\:\\ 0\\.025427294531369358\ \(0\)\
\-\ remains\\:\\ 0\\.025422886253285846\ \(0\)\
\-\ each\\:\\ 0\\.025307354591416642\ \(0\)\
\-\ atrophy\\:\\ 0\\.025250641235497244\ \(0\)\
\-\ always\\:\\ 0\\.025194607097779886\ \(0\)\
\-\ better\\:\\ 0\\.025194607097779886\ \(0\)\
\-\ 2004\\:\\ 0\\.02513923610152443\ \(0\)\
\-\ possibly\\:\\ 0\\.025084512734113048\ \(0\)\
\-\ wnl\\:\\ 0\\.02503042202096219\ \(0\)\
\-\ radiologic\\:\\ 0\\.024871803624844663\ \(0\)\
\-\ painless\\:\\ 0\\.02471838677965372\ \(0\)\
\-\ thus\\:\\ 0\\.024521355790386185\ \(0\)\
\-\ series\\:\\ 0\\.024473367733029338\ \(0\)\
\-\ higher\\:\\ 0\\.024240543851982394\ \(0\)\
\-\ interval\\:\\ 0\\.024150564260094112\ \(0\)\
\-\ pediatric\\:\\ 0\\.02389056434189011\ \(0\)\
\-\ suspicious\\:\\ 0\\.023848601777415712\ \(0\)\
\-\ part\\:\\ 0\\.023848601777415712\ \(0\)\
\-\ again\\:\\ 0\\.023807012218448477\ \(0\)\
\-\ invasion\\:\\ 0\\.023807012218448477\ \(0\)\
\-\ avm\\:\\ 0\\.023604435358506964\ \(0\)\
\-\ form\\:\\ 0\\.023334800577914296\ \(0\)\
\-\ 29\\:\\ 0\\.02326053243796982\ \(0\)\
\-\ that\\:\\ 0\\.023164524699746575\ \(0\)\
\-\ cavernous\\:\\ 0\\.02315129491792347\ \(0\)\
\-\ much\\:\\ 0\\.023115441910480542\ \(0\)\
\-\ teratoma\\:\\ 0\\.02307986155211998\ \(0\)\
\-\ regular\\:\\ 0\\.023044549727324882\ \(0\)\
\-\ decrease\\:\\ 0\\.02294018567004067\ \(0\)\
\-\ schwannoma\\:\\ 0\\.02287188088648453\ \(0\)\
\-\ visual\\:\\ 0\\.022771257770134057\ \(0\)\
\-\ generally\\:\\ 0\\.022608217072575227\ \(0\)\
\-\ intervention\\:\\ 0\\.022419783771711256\ \(0\)\
\-\ either\\:\\ 0\\.02206426132224711\ \(0\)\
\-\ gland\\:\\ 0\\.021680987933916034\ \(0\)\
\-\ caused\\:\\ 0\\.021400431200169167\ \(0\)\
\-\ eye\\:\\ 0\\.0213511802761749\ \(0\)\
\-\ around\\:\\ 0\\.02130244239196585\ \(0\)\
\-\ there\\:\\ 0\\.021239375569719995\ \(0\)\
\-\ done\\:\\ 0\\.021230274463859805\ \(0\)\
\-\ recommended\\:\\ 0\\.021230274463859805\ \(0\)\
\-\ stable\\:\\ 0\\.021112414464258263\ \(0\)\
\-\ appear\\:\\ 0\\.021020218484561332\ \(0\)\
\-\ visualized\\:\\ 0\\.02084110399765357\ \(0\)\
\-\ 80\\:\\ 0\\.020819189228893115\ \(0\)\
\-\ conservative\\:\\ 0\\.02060550850824618\ \(0\)\
\-\ bony\\:\\ 0\\.02056391894927894\ \(0\)\
\-\ solid\\:\\ 0\\.02046153423856407\ \(0\)\
\-\ progressive\\:\\ 0\\.020441323431428484\ \(0\)\
\-\ minimal\\:\\ 0\\.02036134208933743\ \(0\)\
\-\ ct\\:\\ 0\\.020321921990957385\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.020148192436348876\ \(0\)\
\-\ structures\\:\\ 0\\.020054425879804993\ \(0\)\
\-\ process\\:\\ 0\\.020017439168800288\ \(0\)\
\-\ result\\:\\ 0\\.019980742552632557\ \(0\)\
\-\ used\\:\\ 0\\.019980742552632557\ \(0\)\
\-\ management\\:\\ 0\\.01971432554954908\ \(0\)\
\-\ 40\\:\\ 0\\.019628787617314996\ \(0\)\
\-\ studies\\:\\ 0\\.019578205561678823\ \(0\)\
\-\ appears\\:\\ 0\\.019544785458324842\ \(0\)\
\-\ since\\:\\ 0\\.019333186515054442\ \(0\)\
\-\ intact\\:\\ 0\\.019317299251651654\ \(0\)\
\-\ congenital\\:\\ 0\\.019176690502541727\ \(0\)\
\-\ otherwise\\:\\ 0\\.01902525998494443\ \(0\)\
\-\ then\\:\\ 0\\.018893040350780307\ \(0\)\
\-\ complete\\:\\ 0\\.01870842055944082\ \(0\)\
\-\ involving\\:\\ 0\\.018694516256261215\ \(0\)\
\-\ signs\\:\\ 0\\.01865304956318536\ \(0\)\
\-\ because\\:\\ 0\\.01865304956318536\ \(0\)\
\-\ being\\:\\ 0\\.01859832619577398\ \(0\)\
\-\ although\\:\\ 0\\.0181697320960661\ \(0\)\
\-\ less\\:\\ 0\\.018157337930999634\ \(0\)\
\-\ available\\:\\ 0\\.018108087007005367\ \(0\)\
\-\ inflammatory\\:\\ 0\\.018047243567332793\ \(0\)\
\-\ 15\\:\\ 0\\.01803516925204712\ \(0\)\
\-\ type\\:\\ 0\\.01790436850934999\ \(0\)\
\-\ radiation\\:\\ 0\\.01768671091249544\ \(0\)\
\-\ several\\:\\ 0\\.0175109608765641\ \(0\)\
\-\ between\\:\\ 0\\.017341574248819817\ \(0\)\
\-\ 20\\:\\ 0\\.01721844096939454\ \(0\)\
\-\ some\\:\\ 0\\.01679280270690454\ \(0\)\
\-\ age\\:\\ 0\\.016755961614379998\ \(0\)\
\-\ treated\\:\\ 0\\.01662033488406927\ \(0\)\
\-\ decreased\\:\\ 0\\.0165320531220378\ \(0\)\
\-\ years\\:\\ 0\\.016360334965865267\ \(0\)\
\-\ changes\\:\\ 0\\.016130049035901536\ \(0\)\
\-\ infection\\:\\ 0\\.016122030534236165\ \(0\)\
\-\ on\\:\\ 0\\.01612140241868613\ \(0\)\
\-\ cystic\\:\\ 0\\.016074205982482118\ \(0\)\
\-\ edema\\:\\ 0\\.01591823172013181\ \(0\)\
\-\ time\\:\\ 0\\.015819567351190594\ \(0\)\
\-\ shows\\:\\ 0\\.015664454983394912\ \(0\)\
\-\ 10\\:\\ 0\\.0156066913537063\ \(0\)\
\-\ been\\:\\ 0\\.015549632176095137\ \(0\)\
\-\ months\\:\\ 0\\.015535475449480625\ \(0\)\
\-\ if\\:\\ 0\\.015507289854745683\ \(0\)\
\-\ enhancement\\:\\ 0\\.015362038447188421\ \(0\)\
\-\ due\\:\\ 0\\.015341651510459686\ \(0\)\
\-\ cell\\:\\ 0\\.015267650341190962\ \(0\)\
\-\ mild\\:\\ 0\\.01512954518328136\ \(0\)\
\-\ these\\:\\ 0\\.015071582774843025\ \(0\)\
\-\ both\\:\\ 0\\.014883402133686786\ \(0\)\
\-\ symptoms\\:\\ 0\\.014603008054060576\ \(0\)\
\-\ surgery\\:\\ 0\\.01434942913660123\ \(0\)\
\-\ bilateral\\:\\ 0\\.014343947244261678\ \(0\)\
\-\ noted\\:\\ 0\\.014150758557891191\ \(0\)\
\-\ associated\\:\\ 0\\.01406739252921438\ \(0\)\
\-\ imaging\\:\\ 0\\.014026260004287396\ \(0\)\
\-\ can\\:\\ 0\\.014005828554455056\ \(0\)\
\-\ exam\\:\\ 0\\.013435531136886635\ \(0\)\
\-\ up\\:\\ 0\\.013202313032611651\ \(0\)\
\-\ but\\:\\ 0\\.013198022528343482\ \(0\)\
\-\ findings\\:\\ 0\\.013172361799068163\ \(0\)\
\-\ surgical\\:\\ 0\\.012971990289138471\ \(0\)\
\-\ contrast\\:\\ 0\\.012967905789030471\ \(0\)\
\-\ presents\\:\\ 0\\.012839049601690113\ \(0\)\
\-\ also\\:\\ 0\\.012553997843874004\ \(0\)\
\-\ within\\:\\ 0\\.012292382180311092\ \(0\)\
\-\ disease\\:\\ 0\\.01120332353342417\ \(0\)\
\-\ not\\:\\ 0\\.0105363981427063\ \(0\)\
\-\ at\\:\\ 0\\.010080979653387641\ \(0\)\
\-\ year\\:\\ 0\\.008225192807615907\ \(0\)\
